Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/120402
Title: Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors
Author: Castillo-Ávila, Wilmar
Piulats, Josep M.
García del Muro Solans, Xavier
Vidal-Bel, August
Condom i Mundó, Enric
Casanovas i Casanovas, Oriol
Mora, Josefina
Germà Lluch, José Ramón
Capellá, G. (Gabriel)
Villanueva Garatachea, Alberto
Viñals Canals, Francesc
Keywords: Medicaments antineoplàstics
Cisplatí
Quimioteràpia del càncer
Malalties del testicle
Tumors
Càncer
Antineoplastic agents
Cisplatin
Cancer chemotherapy
Testis diseases
Tumors
Cancer
Issue Date: 15-May-2009
Publisher: American Association for Cancer Research
Abstract: Purpose: germ cell tumors (GCT) of the testis are highly curable, but those patients who are refractory to cisplatin (CDDP)-based combination chemotherapy have a poor prognosis. Therefore, identifying new alternatives for treatment remains a priority. Several studies support an important role for angiogenesis in GCTs, suggesting that antiangiogenic treatment might be a good alternative. Sunitinib is an oral multitarget tyrosine kinase receptor inhibitor with antiangiogenic and antitumor activities. In the present study, we evaluated the effect of sunitinib, CDDP, or the combination of both drugs using an orthotopic model of human testicular GCT. Experimental design: mice were implanted with four different testicular tumors: a yolk sac, two choriocarcinomas, and a CDDP-resistant choriocarcinoma variant induced in mice by continuous exposure to CDDP. Mice were treated with vehicle, CDDP, sunitinib, or the combination of both drugs and their effects on tumors were analyzed. Results: we observed a significant inhibition in tumor growth accompanied by longer survival after sunitinib treatment. Combination therapy with CDDP significantly enhanced these effects. Sunitinib induced apoptosis, reduced tumor cell proliferation and tumor vasculature, and inhibited vascular endothelial growth factor receptor 1, 2, and 3 and platelet-derived growth factor receptor α phosphorylation without affecting phosphorylation of other tyrosine kinase receptors. More importantly, tumor growth inhibition induced by sunitinib was also observed in the induced CDDP-resistant choriocarcinoma model. Conclusions: taken together, these results suggest that sunitinib might be a new alternative for treatment of CDDP-refractory patients.
Note: Versió postprint del document publicat a: https://doi.org/10.1158/1078-0432.CCR-08-2170
It is part of: Clinical Cancer Research, 2009, vol. 15, num. 10, p. 3384-3395
Related resource: https://doi.org/10.1158/1078-0432.CCR-08-2170
URI: http://hdl.handle.net/2445/120402
ISSN: 1078-0432
Appears in Collections:Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
576742.pdf1.58 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.